{"title":"基于单克隆抗体的生物技术制备","authors":"Igor Valerievich Korobkin","doi":"10.33920/med-13-2204-05","DOIUrl":null,"url":null,"abstract":"The current biopharmaceutical industry depends on the development of bioinformatics in the search and optimization of the properties of drugs. Compounds and their derivatives, whose metabolism influence, stability, and immunogenicity are confirmed by analytical and computational tools, are the candidates for becoming the drugs against antibodies.","PeriodicalId":12259,"journal":{"name":"Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)","volume":"44 10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biotechnological preparations based on monoclonal antibodies\",\"authors\":\"Igor Valerievich Korobkin\",\"doi\":\"10.33920/med-13-2204-05\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The current biopharmaceutical industry depends on the development of bioinformatics in the search and optimization of the properties of drugs. Compounds and their derivatives, whose metabolism influence, stability, and immunogenicity are confirmed by analytical and computational tools, are the candidates for becoming the drugs against antibodies.\",\"PeriodicalId\":12259,\"journal\":{\"name\":\"Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)\",\"volume\":\"44 10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33920/med-13-2204-05\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33920/med-13-2204-05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Biotechnological preparations based on monoclonal antibodies
The current biopharmaceutical industry depends on the development of bioinformatics in the search and optimization of the properties of drugs. Compounds and their derivatives, whose metabolism influence, stability, and immunogenicity are confirmed by analytical and computational tools, are the candidates for becoming the drugs against antibodies.